KR20210082466A - 샤페론-매개 자가포식작용 조절제로서 유용한 벤족사졸 및 관련된 화합물 - Google Patents

샤페론-매개 자가포식작용 조절제로서 유용한 벤족사졸 및 관련된 화합물 Download PDF

Info

Publication number
KR20210082466A
KR20210082466A KR1020217013722A KR20217013722A KR20210082466A KR 20210082466 A KR20210082466 A KR 20210082466A KR 1020217013722 A KR1020217013722 A KR 1020217013722A KR 20217013722 A KR20217013722 A KR 20217013722A KR 20210082466 A KR20210082466 A KR 20210082466A
Authority
KR
South Korea
Prior art keywords
compound
phenyl
alkyl
chlorobenzo
oxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217013722A
Other languages
English (en)
Korean (ko)
Inventor
아나 마리아 쿠에르보
에브리피디스 가바티오티스
Original Assignee
앨버트 아인슈타인 컬리지 오브 메디신
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앨버트 아인슈타인 컬리지 오브 메디신 filed Critical 앨버트 아인슈타인 컬리지 오브 메디신
Publication of KR20210082466A publication Critical patent/KR20210082466A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217013722A 2018-10-10 2019-10-10 샤페론-매개 자가포식작용 조절제로서 유용한 벤족사졸 및 관련된 화합물 Ceased KR20210082466A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743920P 2018-10-10 2018-10-10
US62/743,920 2018-10-10
PCT/US2019/055493 WO2020077024A1 (en) 2018-10-10 2019-10-10 Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators

Publications (1)

Publication Number Publication Date
KR20210082466A true KR20210082466A (ko) 2021-07-05

Family

ID=70163886

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217013722A Ceased KR20210082466A (ko) 2018-10-10 2019-10-10 샤페론-매개 자가포식작용 조절제로서 유용한 벤족사졸 및 관련된 화합물

Country Status (11)

Country Link
US (1) US12473266B2 (https=)
EP (1) EP3863755A4 (https=)
JP (1) JP7503850B2 (https=)
KR (1) KR20210082466A (https=)
CN (1) CN113195084B (https=)
AU (1) AU2019358074A1 (https=)
BR (1) BR112021006843A2 (https=)
CA (1) CA3115297A1 (https=)
IL (1) IL282069A (https=)
MX (1) MX2021004134A (https=)
WO (1) WO2020077024A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022270702A1 (ko) 2021-06-24 2022-12-29 주식회사 엘지화학 합성가스의 제조방법
WO2024225738A1 (ko) * 2023-04-25 2024-10-31 부산대학교 산학협력단 지방간질환 치료 또는 예방 목적의 fxr/ppar alpha 이중 작용 활성을 가지는 벤즈옥사졸 유도체 화합물

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022015624A1 (en) * 2020-07-16 2022-01-20 Schrödinger, Inc. Substituted dihydropyrazinediones as modulators of the nmda receptor
CN116438166A (zh) * 2020-11-20 2023-07-14 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的n-取代4-(1,3-芳基并噁唑-2-基)苯基化合物
WO2022155333A1 (en) * 2021-01-13 2022-07-21 Albert Einstein College Of Medicine Use of chaperone-mediated autophagy activators for treating or preventing blood cancers and myelodysplastic syndromes
CN114404421B (zh) * 2022-02-28 2023-04-28 同济大学 选择性自噬激活剂qx77在制备干预或治疗糖尿病视网膜病变的药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH469802A (de) * 1966-01-07 1969-03-15 Ciba Geigy Verwendung von Benzoxazol-Derivaten als Scintillator-Substanzen
US5428052A (en) * 1984-09-19 1995-06-27 Centre Internationale De Recherches Dermatologiques (C.I.R.D.) Aromatic heterocyclic derivatives and their therapeutic and cosmetic use
JP3969741B2 (ja) * 1995-11-17 2007-09-05 マーク アンド カンパニー インコーポレイテッド アセチルコリン受容体の修飾因子として役立つ新規置換アリール化合物
WO2003048137A1 (en) 2001-11-30 2003-06-12 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
CN1636037A (zh) 2002-02-21 2005-07-06 西巴特殊化学品控股有限公司 基于内酰胺的颜料及其在生产有色塑料或聚合有色颗粒中的应用
PL1745041T3 (pl) 2004-04-30 2012-11-30 Genentech Inc Inhibitory chinoksalinowe szlaku sygnałowego hedgehog
NZ552397A (en) * 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
JP5301999B2 (ja) 2005-10-31 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション Ｃｅｔｐ阻害薬
RU2462458C2 (ru) * 2006-02-10 2012-09-27 Байомарин Ига Лимитед Лечение миодистрофии дюшена
CA2641880C (en) * 2006-02-10 2014-09-09 Summit Corporation Plc Treatment of duchenne muscular dystrophy
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
CA2737028C (en) 2008-09-23 2017-06-27 Wista Laboratories Ltd. Ligands for aggregated tau molecules
JP2011168515A (ja) 2010-02-17 2011-09-01 Kowa Co エリスロポエチン産生促進作用を有する２−アリールベンゾオキサゾール化合物
US9512092B2 (en) * 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
EP3187495A1 (en) * 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2017160116A2 (ko) * 2016-03-17 2017-09-21 연세대학교 산학협력단 니코틴아미드 포스포리보실트랜스퍼라제 억제용 신규 화합물 및 이를 포함하는 조성물
JP2018087173A (ja) 2016-11-29 2018-06-07 国立大学法人北海道大学 悪性脳腫瘍治療薬
JP7101678B2 (ja) 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022270702A1 (ko) 2021-06-24 2022-12-29 주식회사 엘지화학 합성가스의 제조방법
WO2024225738A1 (ko) * 2023-04-25 2024-10-31 부산대학교 산학협력단 지방간질환 치료 또는 예방 목적의 fxr/ppar alpha 이중 작용 활성을 가지는 벤즈옥사졸 유도체 화합물

Also Published As

Publication number Publication date
CA3115297A1 (en) 2020-04-16
WO2020077024A1 (en) 2020-04-16
JP7503850B2 (ja) 2024-06-21
IL282069A (en) 2021-05-31
EP3863755A4 (en) 2022-08-03
CN113195084B (zh) 2024-04-09
AU2019358074A1 (en) 2021-05-06
JP2022504650A (ja) 2022-01-13
US20210387953A1 (en) 2021-12-16
CN113195084A (zh) 2021-07-30
US12473266B2 (en) 2025-11-18
MX2021004134A (es) 2021-07-16
EP3863755A1 (en) 2021-08-18
BR112021006843A2 (pt) 2021-07-13

Similar Documents

Publication Publication Date Title
KR20210082466A (ko) 샤페론-매개 자가포식작용 조절제로서 유용한 벤족사졸 및 관련된 화합물
JP5271895B2 (ja) 抗糖尿病性の二環式化合物
US8039484B2 (en) Antidiabetic bicyclic compounds
JP7099672B2 (ja) 医薬化合物
JP2008528628A (ja) 抗糖尿病性二環式化合物
EP3509588B1 (en) Bicyclic compounds useful as gpr120 modulators
CN113993845A (zh) 作为治疗cns障碍例如多发性硬化的gpr17调节剂的n-(苯基)-吲哚-3-磺酰胺衍生物和相关化合物
JP7262141B2 (ja) シャペロン介在性オートファジー調節剤として有用な化合物
CN116262724B (zh) 新型氧代吡啶类化合物及其制备方法和用途
TW201925154A (zh) 苯並雜環衍生物及包含其的醫藥組合物
CN114401935B (zh) 离子通道拮抗剂/阻断剂及其用途
FR3067028B1 (fr) Modulateurs de recepteurs nmda, compositions les comprenant et utilisation de ces composes dans le traitement de maladies impliquant le systeme nerveux central
HK40062458A (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
JPH09118660A (ja) 芳香族ヒドロキサム酸誘導体、製造法および剤
WO2020013116A1 (ja) Ｐｔｐ－１ｂ阻害剤およびその用途
HK40018543B (zh) 芳香族化合物及其药物组合物和用途
HK40005335B (en) Bicyclic compounds useful as gpr120 modulators
HK40005335A (en) Bicyclic compounds useful as gpr120 modulators
CN108239029A (zh) 一类四氢异喹啉化合物及其盐的制备和医药用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601